Lauxera Capital Partners

Lauxera Capital Partners is an independent, international, healthcare-focused asset management company. Our growth equity investments focus primarily on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies. Led by entrepreneurial company builders and seasoned healthcare investors with experience across international markets, we empower European healthtech entrepreneurs to deliver the growth promised by their innovations. Lauxera was created in 2020 and has offices in Paris and San Francisco.

Charles Cornevin

Principal

Victor Decrion

Partner and Managing Partner

Edoardo Fracchia

Partner

Pierre Moustial

Co-Founding Partner

Alessandra Petiot

Associate

Victoire Ribert

Senior Associate

Alex Slack

Co-Founder

5 past transactions

Veranex

Private Equity Round in 2022
Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtech innovations.

Lifen

Series C in 2021
Lifen is a 160-person startup, based in Paris, whose ambition is to facilitate the deployment of digital solutions for hospitals, doctors and patients. Since 2015, Lifen has been simplifying the sharing of medical data and has quickly established itself as the leading MSSanté operator in France with more than 600 partner establishments. Every month, Lifen sends 2 million medical documents to 240,000 doctors. Creator of the FHIR France meetup and winner of the ANS interoperability prize 2020, Lifen's ambition is to use its expertise in interoperability with HIS to develop a platform that radically simplifies the technical integration and operational deployment of all types of digital solutions.

Caresyntax

Series C in 2021
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR. Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients.

LUMICKS

Series D in 2021
LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

Reapplix

Series A in 2020
Reapplix ApS, a research and development company, identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds. The company was founded in 2008 and is based in Birkerod, Denmark.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.